Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Phase 2CompletedNCT00174343

Pfizer46 enrolled

Overview

To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Breast Neoplasms

Interventions

exemestane (Aromasin®)DRUG

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive Exclusion Criteria: * Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative

Locations (5)

Pfizer Investigational Site

Bordeaux, France

Pfizer Investigational Site

Clermont-Ferrand, France

Pfizer Investigational Site

Montpellier, France

Pfizer Investigational Site

Poitiers, France

Pfizer Investigational Site

Outcomes

Primary Outcomes

To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)

Secondary Outcomes

To evaluate breast conservative surgery rate; To evaluate intratumoral anti-aromatase activity.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.